[Optimal blood pressure control in patients with diabetes and arterial hypertension: interpreting the BPROAD study]

National and international guidelines for the treatment of arterial hypertension have changed significantly over the last decades. Until 2009, most hypertension guidelines suggested: "the lower the better". This point of view had been revised in the second decade of this century, mainly due to the lack of data supporting low target values. However, the next turnaround was prompted by interpretation of the data from the Systolic Blood Pressure Intervention Trial (SPRINT) in 2015, which provided evidence for a lower rate of cardiovascular events when systolic blood pressure was lowered below 120 mm Hg. Since the SPRINT trial had excluded patients with diabetes, the Blood Pressure Control Target in Diabetes (BPROAD) trial (2025), which included diabetics, received major attention. The BPROAD trial came to similar conclusions as the SPRINT trial, now supporting the benefit of lowering systolic blood pressure below 120 mm Hg for a broader range of patients. However, the method of measuring blood pressure, as well as the individual tolerability of low blood pressure targets, must also be taken into consideration.